On the public citation graph
Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
0 signed · 34 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ccr3.2191openalex-snapshot
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
inferredcites →https://doi.org/10.1002/ccr3.4357openalex-snapshot
Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
inferredcites →https://doi.org/10.1002/jcla.21975openalex-snapshot
High‐performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography‒Tandem Mass Spectrometry
inferredcites →https://doi.org/10.1016/j.leukres.2009.07.009openalex-snapshot
Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature
inferredcites →https://doi.org/10.1038/leu.2016.5openalex-snapshot
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
inferredcites →https://doi.org/10.1053/j.ackd.2015.10.002openalex-snapshot
The Effects of CKD on Cytochrome P450–Mediated Drug Metabolism
inferredcites →https://doi.org/10.1053/j.ajkd.2004.12.017openalex-snapshot
Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence?
inferredcites →https://doi.org/10.1053/j.ajkd.2007.10.039openalex-snapshot
Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
inferredcites →https://doi.org/10.1056/nejm200104053441401openalex-snapshot
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejm200104053441402openalex-snapshot
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
inferredcites →https://doi.org/10.1056/nejmoa022457openalex-snapshot
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa0912614openalex-snapshot
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1002315openalex-snapshot
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1609324openalex-snapshot
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1080/1042819031000079140openalex-snapshot
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1093/annonc/mdq715openalex-snapshot
Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
inferredcites →https://doi.org/10.1093/ndt/17.4.685openalex-snapshot
Renal failure associated with a specific inhibitor of BCR‐ABL tyrosine kinase, STI 571
inferredcites →https://doi.org/10.1182/blood-2006-07-036012openalex-snapshot
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
inferredcites →https://doi.org/10.1182/blood-2013-05-501569openalex-snapshot
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
inferredcites →https://doi.org/10.1200/jco.2015.64.8899openalex-snapshot
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
inferredcites →https://doi.org/10.1248/bpb.b15-00103openalex-snapshot
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1254/jjp.68.431openalex-snapshot
Changes of Hepatic Microsomal Oxidative Drug Metabolizing Enzymes in Chronic Renal Failure (CRF) Rats by Partial Nephrectomy
inferredcites →https://doi.org/10.1345/aph.1g131openalex-snapshot
Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer
inferredcites →https://doi.org/10.2165/00003088-200544090-00001openalex-snapshot
Clinical Pharmacokinetics of Imatinib
inferredcites →https://doi.org/10.3324/haematol.2011.045666openalex-snapshot
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
inferredcites →https://doi.org/10.4009/jsdt.37.239openalex-snapshot
Pharmacokinetics and side effects of imatinib mesilate (Glivec) in a hemodialysis patient with chronic myeloid leukemia
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4653746openalex-extracted
Hemodialysis and Imatinib: Plasma Levels, Efficacy and Tolerability in a Patient with Metastatic Gist
inferred← citeshttps://doi.org/10.1007/s13318-023-00868-yopenalex-snapshot
Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration–Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e28494openalex-snapshot
Hemodialysis and imatinib: Plasma levels, efficacy and tolerability in a patient with metastatic GIST - Case report
inferred← citeshttps://doi.org/10.1177/10781552231160113openalex-snapshot
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients
inferred← citeshttps://doi.org/10.3390/cancers17010092openalex-snapshot
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.3390/molecules27144474openalex-snapshot
Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
showing the first 7 of 8 · page through all 8
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.